New drugs to treat skin and soft tissue infections

Abstract

Due to increasing antimicrobial resistance, a pressing need exists for new antibiotics to treat skin and soft tissue infections. Several newer agents such as tigecycline, daptomycin, and linezolid have been important additions for the treatment of multidrug-resistant pathogens. New drugs in development such as dalbavancin and ceftobiprole will further enhance our ability to treat mixed infections and improve patient compliance. These promising new antimicrobials will likely grow in importance as resistant bacterial strains increase in community-acquired infections.

UV C Light from a Light-Emitting Diode at 275 Nanometers Shortens Wound Healing Time in Bacterium- and Fungus-Infected Skin in Mice

“…SSTIs are infectious diseases with high incidence and complex and diverse conditions. The main management for mild SSTIs is the topical use of antibiotics ( 10 , 11 ). However, the emergence of large numbers of drug-resistant microbes and changes in pathogenic species make the problem of refractory SSTIs increasingly serious and present growing challenges in SSTI management ( 51 ).…”

“…The management of SSTIs is becoming an increasing challenge. Antibiotics are the first choice for the clinical treatment of SSTIs ( 10 , 11 ). However, research on topical skin antibiotics is sorely lacking ( 12 , 13 ), the research cost of new antibiotics is relatively high, and the development cycle is much longer than the breeding speed of drug-resistant microbes ( 10 , 14 ).…”